CRCAIM/CRC-AIM-Public

CRC Model Public and Supplemental Information

CRC-AIM Public Repository

Background

This is a public repository of information related to the Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) microsimulation model. CRC-AIM is a robust colorectal cancer (CRC) natural history and screening model that provides an accessible platform for collaborative simulation studies. This repository was created in the spirit of scientific engagement and transparency, and we will update it periodically as various components of CRC-AIM are added or improved.

Collaborate

We are excited to collaborate with researchers and members of the modeling community to address outstanding questions related to colorectal cancer screening. If you are interested in working with us, please email us at crcaim@exactsciences.com.

Content

v2.0: CRC-AIM v2.0

v1.0: CRC-AIM v1.0 Archival Documents

Publications & Abstracts

This is a comprehensive list of all the abstracts and publications that featured CRC-AIM, along with the corresponding versions of the model and parameters used. (Last Updated June 2024)

Publications

2024

• Kisiel JB, Fendrick AM, Ebner DW, et al. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening. J Med Econ. 2024;27(1):746-753. doi:10.1080/13696998.2024.2349467

2023

• Fendrick AM, Kisiel JB, Brooks D, et al. A Call to Action to Increase Uptake of Follow-Up Colonoscopy After Initial Positive Stool-Based Colorectal Cancer Screening. Popul Health Manag. 2023;26(6):448-450. doi:10.1089/pop.2023.0199

• Ebner D, Kisiel J, Barnieh L, et al. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and Medicare population. J Med Econ. 2023;1-11. doi:10.1080/13696998.2023.2260681

• Fendrick AM, Lieberman D, Chen JV, et al. Impact of eliminating cost-sharing by Medicare beneficiaries for follow-up colonoscopy after a positive stool-based colorectal cancer screening test. Cancer Res Commun. 2023;10.1158/2767-9764.CRC-23-0322. doi:10.1158/2767-9764.CRC-23-0322

• Fendrick AM, Vahdat V, Chen JV, et al. Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests. Popul Health Manag. 2023;26(4):239-245. doi:10.1089/pop.2023.0037

• Vahdat V, Alagoz O, Chen JV, et al. Calibration and validation of the colorectal cancer and adenoma incidence and mortality (CRC-AIM) microsimulation model using deep neural networks. Med Decis Making. 2023;43(6):719-736. doi:10.1177/0272989X231184175.

2022

• Bhatt J, Chen JV, Vahdat V, et al. Cost-Effectiveness of mt-sDNA versus Mailed FIT Outreach for Medicare Advantage Enrollees using the CRC-AIM Microsimulation Model. J Community Med Public Health. 2022;6:266. doi:10.29011/2577-2228.100266

• Fendrick AM, Lieberman D, Vahdat V, et al. Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population. Cancer Prev Res (Phila). 2022;15(10):653-660. doi:10.1158/1940-6207.CAPR-22-0153

• Fendrick MA, Borah BJ, Burak Ozbay A, et al. Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test. Prev Med Rep. 2022;26:101701. doi:10.1016/j.pmedr.2022.101701

• Karlitz JJ, Fendrick AM, Bhatt J, et al. Cost-effectiveness of outreach strategies for stool-based colorectal cancer screening in a Medicaid population. Popul Health Manag. 2021;10.1089/pop.2021.0185. doi:10.1089/pop.2021.0185

2021

• Kisiel JB, Itzkowitz SH, Ozbay AB, et al. Impact of the sessile serrated polyp pathway on predicted colorectal cancer outcomes. Gastro Hep Advances. 2022;1(1):55-62. doi:10.1016/j.gastha.2021.10.007.

• Fendrick AM, Fisher DA, Saoud L, et al. Impact of patient adherence to stool-based colorectal cancer screening and colonoscopy following a positive test on clinical outcomes. Cancer Prev Res (Phila). 2021;14(9):845-850. doi:10.1158/1940-6207.CAPR-21-0075

• Fisher DA, Karlitz JJ, Jeyakumar S, et al. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. J Med Econ. 2021;1. doi:10.1080/13696998.2021.1922240

• Fisher DA, Saoud L, Hassmiller Lich K, et al. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model. Cancer Med. 2021;10(8):2855-2864. doi:10.1002/cam4.3662

• Fisher DA, Saoud L, Finney Rutten LJ, et al. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Curr Med Res Opin. 2021;37(6):1005-1010. doi:10.1080/03007995.2021.1908244

2020

• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLoS One. 2020;15(12):e0244431. doi:10.1371/journal.pone.0244431

• Piscitello A, Saoud L, Matney M, et al. Description and Validation of the Colorectal Cancer and Adenoma Incidence & Mortality (CRC-AIM) Microsimulation Model. BioRxiv.org pre-print | NaturalHistory v1.0 & Screening v1.0

Abstracts

2024

• Fendrick AM, Ebner D, Kisiel JB, et al. Eliminating the colonoscopy backlog with stool-based colorectal cancer screening options. Gastroenterology. 2024;166(5):S-358-S-359. doi:10.1016/s0016-5085(24)01296-4.

• Alagoz O, Fendrick AM, Vahdat V, et al. Impact of racial disparities in the quality of colonoscopy screening on colorectal cancer incidence and mortality: a simulation modeling analysis. Gastroenterology. 2024;166(5):S-1222-S-1223. doi: 10.1016/s0016-5085(24)03263-3

• Ebner D, Fendrick AM, Kisiel JB, et al. Comparison of efficient frontier strategies for guideline-endorsed vs non-endorsed colorectal cancer screening tests. Gastroenterology. 2024;166(5):S-365. doi:10.1016/s0016-5085(24)01309-x.

• Kisiel JB, Fendrick AM, Ebner D, et al. Comparison of efficient frontier strategies for stool-based colorectal cancer screening tests. Gastroenterology. 2024;166(5):S-360-S-361. doi:10.1016/s0016-5085(24)01301-5.

2023

• Limburg P, Itzkowitz S, Lieberman D, et al. Estimated Impact of Adenoma and Colorectal Cancer Early Detection on Health Outcomes and Screening Effectiveness. Early Detection of Cancers Conference. October 10-12, 2023. London, UK.

• Vahdat V, Estes C, Ozbay B, et al. Impact of racial disparities in follow-up colonoscopy for abnormal stool-screening test results on colorectal cancer incidence and mortality: A simulation modeling analysis. 16th AACR Conference on the Sciences of Cancer Health Disparities and the Medically Underserved. October 29-November 2, 2023. Orlando, FL.

• Ebner DW, Kisiel J, Vahdat V, et al. Cost-effectiveness of mt-sDNA vs fecal immunochemical test for colorectal cancer screening in a Medicare population. Am J Gastroenterol. 2023;118(10S):p S316. doi:10.14309/01.ajg.0000951380.78109.e2

• Fendrick AM, Kisiel JB, Ebner DW, et al. Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations. 2023; 41(16): S6642. doi:10.1200/JCO.2023.41.16_suppl.664.

• Fendrick AM, Kisiel JB, Ebner DW, et al. Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies. Journal of Clinical Oncology. 2023; 41(16): S10580. doi:10.1200/JCO.2023.41.16_suppl.10580.

• Ebner DW, Kisiel JB, Estes C, et al. The impact of extending CRC screening to the older population - results from CRC-AIM microsimulation model. Journal of Clinical Oncology. 2023; 41(16): S10567. doi:10.1200/JCO.2023.41.16_suppl.664210567.

• Kisiel JB, Fendrick AM, Borah BJ, et al. Estimated value-based pricing for blood-based colorectal cancer screening test versus multi-target stool DNA test. American Society of Clinical Oncology Annual Meeting. June 2-6, 2023. Chicago, IL.

• Kisiel JB, Fendrick AM, Borah B, et al. Estimated value-based pricing for Guardant Health Shield blood-based colorectal cancer screening test versus multi-target stool DNA test. Digestive Disease Week. May 6-9, 2023. Chicago, IL.

• Fendrick AM, Lieberman DA, Kisiel JB, et al. Colorectal cancer screening with blood-based tests: estimated impact of a 1-, 2-, or 3-year screening interval on benefits and harms compared with annual FIT and triennial mt-sDNA strategies. Digestive Disease Week. May 6-9, 2023. Chicago, IL.

• Kisiel JB, Lieberman DA, Fendrick AM, et al. Estimated adenoma sensitivity threshold needed for blood-based colorectal cancer screening tests to be as effective as stool-based screening tests. Digestive Disease Week. May 6-9, 2023. Chicago, IL.

• Limburg P, Itzkowitz S, Lieberman DA, et al. Estimated impact of adenoma and colorectal cancer early detection on health outcomes and screening effectiveness. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.

• Limburg P, Fendrick AM, Lieberman DA, et al. Cost-effectiveness of stool-based colorectal cancer screening programs from a health system perspective. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.

2022

• Vahdat V, Limburg PJ, Chen JV, et al. Using Deep Neural Networks for Calibration of a Colorectal Cancer Microsimulation Model. SMDM Annual Meeting 2022.

• Fendrick AM, Chen JV, Ozbay AB, et al. Lifetime impact of the change in modality as a result of eliminating cost-sharing for follow-up colonoscopy after a positive stool test for colorectal cancer screening. Am J Gastroenterol. 2022;117(10S)e189-e190. doi:10.14309/01.ajg.0000857704.03887.bd

• Bhatt J, Chen JV, Vahdat V, et al. Cost-effectiveness of mt-sDNA versus mailed FIT outreach for Medicare Advantage enrollees using the CRC-AIM microsimulation model. Journal of Clinical Oncology. 2022; 40(16): S18827. doi:10.1200/JCO.2022.40.16_suppl.e18827.

• Fendrick MA, Vahdat V, Chen JV, et al. Comparison of simulated outcomes between stool-based and blood-based colorectal cancer screening tests. Journal of Clinical Oncology. 2022; 40(16): S10529. doi:10.1200/JCO.2022.40.16_suppl.10529

• Fendrick MA, Lieberman DA, Vahdat V, et al. Cost-effectiveness of waiving coinsurance for follow-up colonoscopy after a positive stool-based colorectal screening test in a Medicare population. Journal of Clinical Oncology. 2022; 40(16): S13624. doi:10.1200/JCO.2022.40.16_suppl.e13624.

2021

• Kisiel JB, Itzkowitz SH, Ozbay AB, et al. Impact of the sessile serrated polyp pathway on predicted colorectal cancer outcomes in the CRC-AIM model. Journal of Clinical Oncology. 2021; 39(15): S10545. doi:10.1200/JCO.2021.39.15_suppl.10545

• Fisher D, Karlitz JJ, Jeyakumar S, et al. Cost-effectiveness of stool-based colorectal cancer screening using reported real-world adherence rates in a Medicare population. Digestive Disease Week 2021.

• Karlitz J, Fendrick M, Bhatt J, et al. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population. 2021;116():pS81-S82. doi:10.14309/01.ajg.0000773200.14901.f4

2020

• Fendrick M, Fischer DA, Saoud L, et al. Predicted Colorectal Cancer Outcomes With Reported Adherence to Follow-Up Colonoscopy After a Positive Stool-Based Test. 2020;115():pS135. doi:10.14309/01.ajg.0000703164.12470.c0

• Fisher D, Saoud L, Rutten F, et al. Lowering the Colorectal Cancer Screening Age Improves Predicted Outcomes In Pre-Medicare and Medicare Populations in the CRC-AIM Microsimulation Model. Am J Gastroenterol. 2020;115():pS136. doi:10.14309/01.ajg.0000703168.63785.e2

• Saoud L, Piscitello A, Fendrick AM, et al. Impact Of Aligned Screening Interval On Screening Outcomes Using The CRC-AIM Microsimulation Model. ISPOR 2020.

• Saoud L, Fendrick AM, Piscitello A, et al. More Fecal Immunochemical Tests Are Needed To Match The Clinical Benefit Of Equivalent Numbers Of Multitarget Stool DNA Tests: CRC-AIM Microsimulation Model Results. Digestive Disease Week 2020.

• Fendrick AM, Piscitello A, Borah BJ, et al. Microsimulation study of life-years gained from screening versus follow-up colonoscopy using the CRC-AIM model. Digestive Disease Week 2020.

• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of imperfect adherence to stool-based colorectal cancer screening strategies on comparative effectiveness using the CRC-AIM microsimulation model. Digestive Disease Week 2020.

• Limburg PJ, Saoud L, Borah BJ, et al. Higher impact on clinical outcomes from delays in colorectal cancer screening with the fecal immunochemical test vs multitarget stool DNA: CRC-AIM microsimulation model results. Digestive Disease Week 2020.

2019

• Piscitello A, Matney M, Saoud L, et al. Validating a Novel Colorectal Cancer Natural History Microsimulation Model: The Colorectal Cancer and Adenoma Incidence Microsimulation Model (CRC-AIM). SMDM Annual Meeting 2019. | NaturalHistory v1.0